Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. - Wikidata - wikimedia - TriplyDB

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial.

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial.

http://www.wikidata.org/entity/Q34583699

about

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis Sequence of treatment in locally advanced and metastatic renal cell carcinoma Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities Immunotherapy for metastatic renal cell carcinoma.Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: a systematic review Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report Adjuvant therapy for renal cell carcinoma: past, present, and future Targeted therapies in the management of renal cell carcinoma: role of bevacizumab Targeted treatments in advanced renal cell carcinoma: focus on axitinib.Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy Update on vaccine development for renal cell cancer.Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.Improving outcomes in patients with advanced renal cell carcinoma.Immunotherapy for renal cell cancer in the era of targeted therapy.Sorafenib in the management of metastatic renal cell carcinoma Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma.Management of metastatic renal cell carcinoma: current trends.The application of high-dose interleukin-2 for metastatic renal cell carcinoma.Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer.Optimizing recent advances in metastatic renal cell carcinoma.UK guidelines for the systemic treatment of renal cell carcinoma.Immunotherapeutic strategies in kidney cancer--when TKIs are not enough.A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia.Treatment of metastatic renal cell carcinoma.Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.Present and future therapeutic options for locally advanced and metastatic renal cell carcinoma.Systemic therapy for advanced renal cell carcinoma.Targeted therapy in renal cancer.Optimizing treatment for metastatic renal cell carcinoma.Bevacizumab in combination with IFN-α in metastatic renal cell carcinoma: the AVOREN trial.Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis.

P2860

Q24606852-739D7C7D-72E1-4031-98DF-71D2ABB001BD Q26746200-4EF45F12-C215-4D7A-AD17-9B52C16A221B Q26773653-6D71C758-9F2B-4BC4-BB4C-297FDAA4E9EB Q26775769-4507D197-C2F2-47EA-A1E4-32CFD045DE69 Q26852437-BCD956E6-0160-4B33-80BA-3BF9873547A9 Q30234458-31FBC1AD-175B-4092-AF35-9E5EB7767BDD Q33591376-0F3DA7DB-1854-4E4D-8A91-F755DEA1FBF8 Q33716744-8C527C9D-F7FE-4AC6-B418-DB2822E5F14E Q33762689-1409E55F-B9B8-476A-893E-FF2B6A935CFA Q34005127-1BA62B94-E0EF-45CE-99E2-345A4ED54B61 Q34611205-B2D3F1C9-BA8D-4F6D-9190-01B74ED826FA Q34661185-01848E94-80CD-418F-B691-48FAC137C639 Q34806694-7669E047-B751-471D-B899-512AB3DBBB3D Q34982554-A8763BF0-CBB8-4F91-9A64-6471B75FEB52 Q35044419-6FD88AC2-4F77-4327-8115-446AE9CE1FDE Q35583662-1FA01331-977B-4963-B255-3A93143140E5 Q36318627-68420F44-C891-4C48-8C2B-67ABA90264DE Q36989720-1447D2AA-43B1-41B8-9FE6-30044818D0B8 Q37071204-52C43A75-02AE-4277-8BB7-1874856CE720 Q37118967-35ACCAB6-849E-4AAF-A66D-7EE2B36A0072 Q37183451-2BEC983B-700A-4FEF-988A-1F45A5FEA90A Q37205789-CF4C57A6-61AA-4700-95AF-5B91B67B794D Q37287465-EBCED6BF-8CB8-47E7-B31E-85E4E4D0B3C1 Q37299992-86FB4FBD-3A11-4E2B-901D-2605A37F1D7B Q37355884-D1056455-2FD7-4873-A010-9C157EA44642 Q37369958-F838DC3C-8AB1-4F6C-8D78-22FD11FE510F Q37406017-AEFF2A3A-3035-4737-B1C0-0C94AE8B7F5A Q37428186-C3BD0635-3803-4E93-B1F5-5B179CE5B6A4 Q37487540-695DED23-7EB0-4D93-9BF0-5B26DE668E10 Q37527800-FEDBE326-B4B0-40EA-B1F6-A41308B05F4D Q37622928-8716A540-CFAA-4999-8057-01F646DE8CD2 Q37748477-63AF3671-E68B-4498-952E-2598E90DF71C Q37768461-AAD5429B-CBB5-435A-B86B-39DDC74391E5 Q37809571-267F1758-B448-42AC-9618-A99407D164D8 Q37838448-3463BDB1-0380-412C-842A-CF525676FA65 Q37905583-74B94277-C42B-4EFD-9750-BD524D82A63D Q37905587-7B208DAE-5672-40F9-B616-6BB14667A97C Q37960915-054FB9FE-1F3F-41A2-A1AC-6D293A832F05 Q38058530-1220F0D9-F24E-48AE-8FCF-D74C743F7D3C Q38068922-6028B8BC-AB2F-498D-8E88-958A69C7D005

P2860

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial.

http://www.wikidata.org/entity/Q34583699

description

2007 nî lūn-bûn

@nan

2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Medroxyprogesterone, interfero ...... a randomized controlled trial.

@ast

Medroxyprogesterone, interfero ...... a randomized controlled trial.

@en

Medroxyprogesterone, interfero ...... a randomized controlled trial.

@nl

type

label

Medroxyprogesterone, interfero ...... a randomized controlled trial.

@ast

Medroxyprogesterone, interfero ...... a randomized controlled trial.

@en

Medroxyprogesterone, interfero ...... a randomized controlled trial.

@nl

prefLabel

Medroxyprogesterone, interfero ...... a randomized controlled trial.

@ast

Medroxyprogesterone, interfero ...... a randomized controlled trial.

@en

Medroxyprogesterone, interfero ...... a randomized controlled trial.

@nl

P1433

Q34583699-CFF4007C-D8C0-4EC2-A258-CD8D18722BEA

P1476

Q34583699-EBFBA090-8030-4FC1-980A-176BDA090DDA

P2093

Q34583699-01AE6513-C857-42D9-B826-7A52763F9DCC

Q34583699-1792F560-C330-4772-8ABE-883FC9A587ED

Q34583699-1B7F15A4-F2D5-4B1F-A630-BA5CC8FFE03C

Q34583699-350671B0-6D73-438E-B8BD-506C8562BAD3

Q34583699-599275C9-E8D6-45CC-B227-42A3148D6E79

Q34583699-7FE00993-7F0A-4175-91E1-7BD57C342C3B

Q34583699-C7D210A5-4718-476C-8A19-58E1DC97EFC5

P2860

Q34583699-3EBBE897-3E21-44C2-BF92-7C502FA83E59

Q34583699-62F4F2C7-121A-4551-A274-88B2EC601290

P304

Q34583699-4A38E804-7A03-4825-AA98-49D890C01D99

P31

Q34583699-2C5C90C5-57B9-4411-83C9-0036D2EE8D4F

P356

Q34583699-83B6A09D-255B-499A-B717-220AC02A4025

P407

Q34583699-DD59302C-34A1-494B-97EC-074A96F622A2

P433

Q34583699-2D86B247-BAFC-4BCA-88E5-2DDBF7BAFF5D

P478

Q34583699-78F4A796-600C-40FC-926E-D73E9D737D8A

P50

Q34583699-2C23986A-06AD-406C-B5C4-5EA64022E507

Q34583699-8EE2AE9D-DBA1-4196-A7B2-8E4B221215CC

Q34583699-E85E0EE0-708A-46A9-AA8C-289F62366F8F

P577

Q34583699-A8734EEB-CC96-44C4-ACA0-5CF0385ACE2E

P698

Q34583699-87B6D5C2-8FD4-4B06-BFEB-15D1C0FCE078

P921

Q34583699-1e208755-d4e1-4bf2-8d54-fa013935502e

P356

P1433

P1476

Medroxyprogesterone, interfero ...... a randomized controlled trial.

@en

P2093

Armelle Caty

http://www.w3.org/2001/XMLSchema#string

Christine Chevreau

http://www.w3.org/2001/XMLSchema#string

David Perol

http://www.w3.org/2001/XMLSchema#string

Emmanuel Sevin

http://www.w3.org/2001/XMLSchema#string

French Immunotherapy Intergroup

http://www.w3.org/2001/XMLSchema#string

Remy Delva

http://www.w3.org/2001/XMLSchema#string

Sylvie Negrier

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen.

P304

2468-2477

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.23056

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Bernard Escudier

Jacques-Olivier Bay

P577

2007-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17932908

http://www.w3.org/2001/XMLSchema#string

P921